Publication Name	World Journal of Clinical Oncology
Manuscript ID	120188
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Compound Muji Granules enhances cisplatin efficacy against alpha-fetoprotein-producing gastric cancer by suppressing epidermal growth factor receptor signaling
Manuscript Source	Unsolicited Manuscript
All Author List	Hui Li, Li Wang, Sen Zuo, Wen-Ting He and Tong Zhang
Funding Agency and Grant Number	Funding Agency Grant Number Natural Science Foundation of Xinjiang Uygur Autonomous Region No. 2022D01C561
Corresponding Author	Tong Zhang, Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, o. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. ashtray45671@outlook.com
Key Words	Compound Muji Granules; Alpha-fetoprotein-producing gastric cancer; Cisplatin; Epidermal growth factor receptor-phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin pathway; FU97 cells
Core Tip	Compound Muji Granules (CMG) markedly inhibited proliferation, migration, and invasion of alpha-fetoprotein (AFP)-producing gastric cancer FU97 cells, reduced AFP secretion, and induced G0/G1 arrest and apoptosis. Notably, CMG combined with cisplatin produced stronger growth inhibition and pro-apoptotic effects than either agent alone. Network pharmacology and molecular docking identified epidermal growth factor receptor (EGFR) as a key CMG target, and quantitative real-time polymerase chain reaction/Western blotting confirmed that the combination suppresses the EGFR-phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin pathway at both messenger RNA and protein levels. Importantly, the antitumor activity of CMG plus cisplatin persisted in an EGFR-driven FU97 model, supporting CMG as a potential chemosensitizer for AFP-producing gastric cancer.
Citation	Li H, Wang L, Zuo S, He WT, Zhang T. Compound Muji Granules enhances cisplatin efficacy against alpha-fetoprotein-producing gastric cancer by suppressing epidermal growth factor receptor signaling. World J Clin Oncol 2026; In press

Received	2026-02-24 02:52
Peer-Review Started	2026-02-24 02:52
First Decision by Editorial Office Director	2026-03-27 10:21
Return for Revision	2026-03-27 10:21
Revised	2026-04-22 09:23
Publication Fee Transferred	2026-04-29 10:29
Second Decision by Editor	2026-05-27 02:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-27 05:45
Articles in Press	2026-05-27 05:45
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com